Ambra Pozzi

Vanderbilt research has revealed an important mechanism in the kidney by which a cell surface receptor known as DDR1 fans the flames of inflammation and fibrosis that ultimately lead to kidney failure. Read More

A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently. Read More

A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases. Read More

Vanderbilt’s Division of Nephrology and Hypertension has received a five-year, $5 million federal grant to provide core research services in the fight against kidney disease. Read More

Interventions that increase circulating levels of compounds called EETs may improve insulin sensitivity and treat hypertension. Read More

Integrins are membrane proteins made up of combinations of different “alpha” and “beta” subunits that enable cells throughout the body to interact with their surroundings. Read More

Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have it because kidney disease often develops slowly with minimal symptoms. Read More

A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process. Read More

Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer. Read More

Targeting the production of molecules that promote tumor blood vessel development offers a new path for treating lung cancer. Read More